US › Healthcare

Candel Therapeutics Inc (CADL)

US · Healthcare · Biotechnology

$10.51+4.37%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-8.9M
Profit YoY
-220.1%
EPS
$-0.14
EPS estimate
$-0.33

EPS came in at -0.14 against a street estimate of -0.33 — a beat of 57.6%.

Key statistics

Market cap
$733.4M
Forward P/E
43.5
P/B
5.32
Book value
$1.88
EPS (TTM)
$-1.01
52-week high
$11.36
52-week low
$4.35
50-day MA
$9.16
200-day MA
$6.54
Beta
-0.51

Analyst view

Analysts rate Candel Therapeutics Inc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $20.50.

Shareholding

Insiders
15.53%
Institutions
60.21%

Largest institutional holders

FundStake
FMR Inc15.00%
RTW INVESTMENTS, LLC8.76%
BlackRock Inc4.24%
Saturn V Capital Management LLC3.95%
Portolan Capital Management, LLC3.95%
Vanguard Capital Management, LLC3.36%
Vestal Point Capital LP1.54%
Millennium Management LLC1.45%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Candel Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.